Alam S M, Kyriakides T, Lawden M, Newman P K
Department of Neurology, Middlesbrough General Hospital, Cleveland, UK.
J Neurol Neurosurg Psychiatry. 1993 Nov;56(11):1219-20. doi: 10.1136/jnnp.56.11.1219.
A randomised double-blind placebo-controlled trial of intravenous methylprednisolone versus oral methylprednisolone at equivalent high dose was carried out on 35 patients with an acute relapse of multiple sclerosis (MS). After baseline evaluation each was randomly allocated to oral treatment and intravenous placebo or intravenous treatment and oral placebo, receiving 500 mg of methylprednisolone for five consecutive days and with reassessment at days five and twenty-eight. There was no significant difference in response when disability or functional scores were compared in the two groups. Adverse effects were minor and equally distributed. In this study oral treatment with methylprednisolone was as effective as intravenous treatment in acute relapse of MS.
对35例多发性硬化症（MS）急性复发患者进行了一项随机双盲安慰剂对照试验，比较等效高剂量静脉注射甲泼尼龙与口服甲泼尼龙的效果。在基线评估后，每位患者被随机分配接受口服治疗和静脉注射安慰剂或静脉注射治疗和口服安慰剂，连续五天接受500毫克甲泼尼龙治疗，并在第5天和第28天进行重新评估。比较两组的残疾或功能评分时，反应无显著差异。不良反应轻微且分布均匀。在本研究中，甲泼尼龙口服治疗在MS急性复发中与静脉注射治疗同样有效。
